Musculoskeletal
sarcomas are aggressive malignancies of bone and
soft tissues often affecting children and adolescents. Histone deacetylase
inhibitors (HDACi) have been proposed to counteract cancer stem cells
(CSCs) in solid neoplasms. When tested in human osteosarcoma, rhabdomyosarcoma,
and Ewing’s sarcoma stem cells, the new HDACi MC1742 (<b>1</b>) and MC2625 (<b>2</b>) increased acetyl-H3 and acetyl-tubulin
levels and inhibited CSC growth by apoptosis induction. At nontoxic
doses, <b>1</b> promoted osteogenic differentiation. Further
investigation with <b>1</b> will be done in preclinical sarcoma
models